
|Articles|August 15, 2003
Novartis to market antibody fragment
Basel, Switzerland-Novartis Ophthalmics will have exclusive license to develop and market ranibizumab (Lucentis, formerly known as rhuFab V2), an anti-VEGF antibody fragment, outside North America under a new agreement with Genentech Inc.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Metformin use associated with reduced incidence of intermediate AMD
2
Ocumetics reports first-in-human data investigational accommodating IOL in severe vision loss
3
EnVision Summit 2026: Ultimate gathering place for ophthalmic education
4
Sandoz Canada launches aflibercept biosimilar, Enzeevum
5




























